Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of "Hold" by Brokerages

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has received a consensus rating of "Hold" from the seven analysts that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $3.90.

A number of research firms recently weighed in on AKYA. Canaccord Genuity Group lowered shares of Akoya Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Piper Sandler lowered shares of Akoya Biosciences from an "overweight" rating to a "neutral" rating and set a $2.40 price target on the stock. in a research report on Wednesday, March 5th. Finally, Stephens restated an "overweight" rating and set a $3.50 price target on shares of Akoya Biosciences in a research report on Tuesday.

Hedge Funds Weigh In On Akoya Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of AKYA. GSA Capital Partners LLP boosted its holdings in Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company's stock valued at $845,000 after purchasing an additional 144,903 shares during the last quarter. State Street Corp lifted its holdings in shares of Akoya Biosciences by 4.2% in the 3rd quarter. State Street Corp now owns 453,296 shares of the company's stock worth $1,233,000 after acquiring an additional 18,361 shares during the last quarter. Barclays PLC lifted its holdings in shares of Akoya Biosciences by 320.9% in the 3rd quarter. Barclays PLC now owns 39,472 shares of the company's stock worth $107,000 after acquiring an additional 30,095 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Akoya Biosciences in the 4th quarter worth approximately $28,000. Finally, SVB Wealth LLC acquired a new position in shares of Akoya Biosciences in the 4th quarter worth approximately $1,180,000. 79.42% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Akoya Biosciences Price Performance

Shares of AKYA stock traded up $0.06 on Friday, reaching $1.62. 470,724 shares of the company were exchanged, compared to its average volume of 345,565. The company has a market cap of $80.31 million, a price-to-earnings ratio of -1.37 and a beta of 1.32. The business has a 50-day moving average price of $2.32 and a 200 day moving average price of $2.53. The company has a debt-to-equity ratio of 5.62, a quick ratio of 1.85 and a current ratio of 2.75. Akoya Biosciences has a 1 year low of $1.38 and a 1 year high of $5.16.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). The business had revenue of $21.34 million for the quarter, compared to analyst estimates of $21.34 million. Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. Equities research analysts forecast that Akoya Biosciences will post -0.96 earnings per share for the current fiscal year.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.